home
portfolio
team
careers
contact
investor portal
home
portfolio
team
careers
contact
investor portal
Nextech Invest
Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Results
Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Results
Post navigation
Previous Post
Previous
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors
Next Post
Next
Turning Point Therapeutics Announces Appointment of Steve Sabus as Chief Commercial Officer